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AbstrACt
Introduction Relieving obstructive jaundice in inoperable 
pancreato- biliary cancers improves quality of life and 
permits chemotherapy. Percutaneous transhepatic 
cholangiography with drainage and/or stenting relieves 
jaundice but can be associated with significant morbidity 
and mortality. Percutaneous transhepatic biliary drainage 
(PTBD) in malignant biliary obstruction was therefore 
examined in a national cohort to establish risk factors for 
poor outcomes.
Methods Retrospective study of adult patients undergoing 
PTBD for palliation of pancreato- biliary cancer in England 
between 2001 and 2014 identified from Hospital Episode 
Statistics. Multivariate logistic regression analysis was 
used to examine associations with mortality and the need 
for a repeat PTBD within 2 months.
results 16 822 patients analysed (median age 72 (range 
19–104) years, 50.3% men). 58% pancreatic and 30% 
biliary tract cancer. In- hospital and 30- day mortality were 
15.3% (95% CI 14.7% to 15.9%) and 23.1% (22.4%–
23.8%), respectively. 20.2% suffered a coded complication 
within 3 months. Factors associated with 30- day mortality: 
age (≥81 years OR 2.68 (95% CI 2.37 to 3.03), p<0.001), 
increasing comorbidity (Charlson score 20+, 3.10 
(2.64–3.65), p<0.001), pre- existing renal dysfunction 
(2.37 (2.12–2.65), p<0.001) and non- pancreatic cancer 
(unspecified biliary tract 1.28 (1.08–1.52), p=0.004). 
Women had lower mortality (0.91 (0.84–0.98), p=0.011), 
as did patients undergoing PTBD in a ‘higher volume’ 
provider (84–180 PTBDs per year 0.68 (0.58–0.79), 
p<0.001).
Conclusions In patients undergoing PTBD for the 
palliation of malignant biliary obstruction, 30- day mortality 
was high at 23.1%. Mortality was higher in older patients, 
men, those with increasing comorbidity, a cancer site other 
than pancreas and at ‘lower- volume’ PTBD providers.
IntroduCtIon
Jaundice may arise from biliary obstruction by 
cholangiocarcinoma, pancreatic, duodenal, 
gallbladder or primary or secondary liver 
malignancies. The majority of such patients 
present at a late stage and are unsuitable 
for curative surgery. Biliary obstruction may 
impair quality of life and result in pruritus, 
cholangitis and liver failure.1 2 In patients who 
are unsuitable for curative resection, relief 
of obstructive jaundice improves quality of 
life.3 4 Furthermore, biliary drainage can be a 
bridge to palliative chemotherapy, improving 
survival in locally advanced and metastatic 
pancreatic cancer,5 and in advanced biliary 
tract cancer.6 7
Biliary drainage can be achieved surgically, 
via endoscopic retrograde cholangiopan-
creatography (ERCP) or via percutaneous 
transhepatic cholangiography (PTC). The 
approach employed will depend on whether 
the cancer is operable and its location. PTC 
facilitates external and internal biliary tree 
strengths and limitations of this study
 ► This is the largest study to date examining the out-
comes of patients undergoing percutaneous tran-
shepatic biliary drainage (PTBD) for unresectable 
biliary tract obstruction.
 ► Use of Hospital Episode Statistics (HES) database 
ensures high- quality diagnostic, procedural and 
mortality data at a national level.
 ► Diagnostic and procedural coding relevant to study 
locally validated, confirming a high level of accuracy.
 ► Accuracy of HES database dependent on quality of 
medical records and the staff coding the records.
 ► Information relevant to use of PTBD not recorded in 
HES includes pathology results, use of antibiotics, 
technical details of PTBD and seniority/experience 
of radiologist performing procedure.
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drainage and is the primary method of relieving biliary 
obstruction for malignant lesions above the level of the 
common hepatic duct,8 or when ERCP has failed to 
relieve more distal obstruction. However, percutaneous 
transhepatic biliary drainage (PTBD) is associated with 
significant mortality and morbidity, with complications 
reported to be as high as 30%, including cholangitis, 
sepsis, haemorrhage and stent blockage.2
Case series and randomised controlled trials examining 
outcomes of PTBD in malignancy have typically involved 
less than 100 patients. National data were therefore used 
to examine unselected outcomes for PTBD in a very large 
cohort of inoperable pancreato- biliary cancer to estab-
lish factors associated with poor outcomes, such as early 
mortality.
Methods
data source
Hospital Episode Statistics (HES) is an administrative 
database that records all elective and emergency care 
episodes in English National Health Service hospitals. 
A unique identifier allows individuals to be followed 
through their hospital admissions and outpatient atten-
dances. Each recorded episode contains diagnostic, 
procedural, demographic, administrative and geograph-
ical information. Diagnostic data are coded using the 
International Classification of Diseases V.10 (ICD-10) 
and procedures coded using the Office of Population 
Censuses and Surveys Classification of Interventions and 
Procedures fourth revision (OPCS-4). HES is linked to 
the Office of National Statistics mortality data, providing 
information on date and cause of death.9
study population
Inclusion criteria
All patients aged over 18 years undergoing PTBD between 
2001 and 2014 with a diagnosis of cancer of the pancreas, 
gallbladder, liver, intrahepatic bile ducts, small bowel or 
unspecified bile duct cancer were included. PTBD and 
diagnosis data were identified by OPCS-4 and ICD-10 
coding, respectively. All analyses relate to the first PTBD 
each patient underwent.
Exclusion criteria
Patients were excluded if they were diagnosed with cancer 
more than 2 years prior to their first PTBD or more than 
6 months after their first procedure in order to exclude 
patients with potentially incorrectly coded diagnoses 
and to allow for delays in coding of a cancer diagnosis. 
Patients who went on to have a surgical resection of their 
malignancy after PTBD were identified by OPCS-4 coding 
and were excluded, as were those with incomplete demo-
graphic data.
Patient and public involvement
This research was carried out without patient or public 
involvement.
Validation of Ptbd population
To assess the validity of the PTBD population, the number 
of PTBDs undertaken at University Hospital Birmingham 
(UHB) between April 2009 and April 2014 that met the 
study criteria were extracted from the UHB radiology 
database and compared with the number of PTBDs coded 
in HES at UHB for the same period.
study variables and data extraction
Demographics
Demographic data including age, gender and ethnicity 
were extracted from coding at the time of PTBD. Age was 
divided into quintiles. Ethnicity was classified into White, 
Asian or Asian British, Black or Black British, Mixed, any 
other ethnic group and unknown.
Comorbidity
The Charlson comorbidity index was calculated using 
ICD-10 codes for secondary diagnoses, excluding any 
form of cancer, and divided into five categories by number 
of comorbidities. The derivation of Charlson score from 
ICD-10 coding in HES has previously been assessed and 
found to be valid for assessing comorbidity in patients 
undergoing surgery for urological cancer. There was an 
83% agreement between Charlson scores derived from 
ICD-10 coding in HES and those derived from ICD-9 
comorbidity codes.10
socioeconomic status
Deprivation was assessed using the index of multiple 
deprivations 2007, which is calculated from an aggre-
gate score for each English lower layer super output area 
(LSOA), based on income, employment, health, educa-
tion, training and skills, barriers to housing and services, 
crime and living environment.11 Patients’ LSOAs are 
recorded in HES based on postcode of residence and 
deprivation was analysed in quintiles, with 1 being the 
most and 5 the least deprived.
healthcare provider
Healthcare providers were stratified by their PTBD 
volume per year into quintiles.
endoscopic retrograde cholangiopancreatography
Patients who had undergone an ERCP prior to their 
PTBD were identified by OPCS-4 coding.
outcomes
Outcomes were calculated from the date of the first 
PTBD and included in- hospital, 7 and 30 day mortality 
and median survival. Emergency readmissions into any 
hospital within 30 days of discharge post- PTBD were 
also identified. The proportion of patients that suffered 
complications related to PTBD was identified using 
ICD-10 coding. Patients undergoing chemotherapy after 
their PTBD were identified by ICD-10 (Z080, Z511, Z542, 
Z926) and OPCS 4 codes (X70, X71, X72, X73, X352, 
X384).
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ethics
HES includes only pseudonymised data and therefore 
ethical approval is not necessary. It is available under 
a data sharing agreement for the purposes of service 
evaluation.
statistical analysis
All statistical analyses were carried out using STATA SE 
V.14 (StataCorp LP). Univariate analyses were performed 
to compare characteristics of included and excluded 
patients, as well as factors affecting the rates of chemo-
therapy (tables 1 and 2 respectively), using χ2 tests for 
categorical variables. Bonferroni correction was applied 
to these analyses and results were considered statistically 
significant if p values were <0.0045. A multivariate model 
was produced to examine associations with mortality 
following adjustment for the variables identified on 
univariate analyses. A further multivariate model was 
produced to examine associations with needing a further 
PTBD procedure, adjusting for the variables identified on 
univariate analysis. In the multivariate analyses p- values of 
<0.05 were considered statistically significant. Odds ratios, 
95% CI and p values were generated from the multivar-
iate model. Unadjusted Kaplan Meier analysis was under-
taken for 7- day and 30- day mortality, split by age quintile.
results
study population
Between 2001 and 2014, 19 525 patients underwent PTBD 
for one of the study malignancies. 1006 patients were 
diagnosed with cancer more than 2 years before or more 
than 6 months after their PTBD and were excluded. A 
further 1438 patients who underwent potentially curative 
resection after their PTBD and 259 patients with incom-
plete demographic data were also excluded, giving a final 
study population of 16 822 (figure 1).
Patient characteristics
The characteristics of the study population and excluded 
patients are shown in table 1. 50.3% of patients were men 
and the median age was 72 (range 19–104) years. 58% of 
patients had pancreatic cancer, with malignant neoplasm 
of the liver and intrahepatic bile ducts accounting for 
30.1% of patients, of whom 90.4% had a diagnosis of 
cholangiocarcinoma. 86.3% of patients underwent only 
one procedure, with a range from 1 to 15 and 61.8% had 
undergone a previous ERCP. 57.9% of patients under-
going prior ERCP had their PTBD carried out during the 
same admission episode, indicating that the PTBD was 
likely a salvage procedure.
Validation
The number of PTBDs meeting the study criteria at 
UHB between April 2009 and April 2014 was 321 and 
the number of PTBDs coded in HES for UHB in the 
same time period was 305 (95%), suggesting misclassifi-
cation in HES is unlikely. Univariate analysis comparing 
excluded and included patients is in table 1. There was 
no difference in gender between excluded and included 
patients. Excluded patients were younger (under 61 years 
of age (23.6% vs 19.4%, p=0.005)), more likely to be 
white (84.3% vs 78.4%, p<0.001), have less comorbidities 
(<5 65.6% vs 56.2%, p<0.001) and were less likely to have 
pancreatic cancer (51.1% vs 58%, p<0.001). Only 259 
(1.3%) out of 19 525 patients were excluded for incom-
plete demographic data.
Crude mortality and emergency readmission rates
5.2% (95% CI 4.9% to 5.6%) of patients died within 7 
days of PTBD, 15.3% (95% CI 14.7% to 15.9%) died in 
hospital and 23.1% (95% CI 22.4% to 23.8%) died within 
30 days of their first PTBD. Median survival was 92 (IQR 
33–242) days and the median length of stay after PTBD 
was 9 (IQR 4–16) days. The emergency readmission rate 
within 30 days was 20.8% (95% CI 20.1% to 21.5%).
Complications
5.9% of patients suffered a complication within 7 days of 
their PTBD, and 20% within 3 months. Infection was the 
most common complication with 2.4% of patients experi-
encing this within a week, and 9% within a month (cholan-
gitis 3.9%, sepsis 3.9%, bacterial infection of unspecified 
site 0.8%, cholecystitis 0.4%). 2.9% of patients had a code 
for stent displacement or blockage (mean time to stent 
blockage or displacement 6.3 (SD 8.6) months) and 2.1% 
for gastrointestinal haemorrhage. The rate of post- PTBD 
acute kidney injury was 0.9% within 7 days and 2.4% 
within 3 months.
Chemotherapy
38.7% of patients under the age of 61 were coded as 
undergoing chemotherapy after their PTBD (table 2). 
This was less common in older patients: 62–68 years 
(30.4%), 69–74 (23.7%), 75–80 (13.5%) and ≥81 (2.5%) 
(p<0.001). Patients with pancreatic cancer were the most 
likely to receive chemotherapy at 22.8%. Over the time 
period studied, more patients received chemotherapy 
after PTBD (2001/2002 13.1%, 2013/2014 27.3% 
(p<0.001).
univariate regression analysis
Age, gender, comorbidity, deprivation, pre- existing renal 
failure, type of cancer, year of procedure and provider 
PTBD volume were all found to be associated with 
mortality and adjusted for in the subsequent multivariate 
analyses.
Multivariate regression analysis
Demographic factors and mortality
The results of the multivariate regression analysis for 
demographic factors associated with mortality are shown 
in table 3. Age was strongly associated with mortality, with 
the ≥81 age group having the highest 7- day (2.87 (95% CI 
2.23 to 3.69) p<0.001), in- hospital (3.47 (95% CI 2.97 to 
4.05), p<0.001) and 30- day mortality (2.68 (95% CI 2.37 
to 3.03), p<0.001). Women had a better outlook, with 
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Table 1 Study and excluded patient characteristics
Included patients Excluded patients P value
Sex
  Male 8465 (50.3%) 527 (52.4%) 0.203
  Female 8357 (49.7%) 479 (47.6%)
Age
  <61 3267 (19.4%) 237 (23.6%) 0.005
  62 to 68 3082 (18.3%) 173 (17.2%)
  69 to 74 3253 (19.3%) 179 (17.8%)
  75 to 80 3412 (20.3%) 219 (21.8%)
  ≥81 3808 (22.6%) 198 (19.7%)
Deprivation
  1 3258 (19.4%) 183 (18.2%) 0.08
  2 3284 (19.7%) 199 (19.8%)
  3 3356 (19.5%) 189 (18.8%)
  4 3453 (20.5%) 201 (20.0%)
  5 3343 (19.9%) 225 (22.4%)
  Unknown 71 (0.4%) 9 (0.9%)
Ethnic group
  White 13 190 (78.4%) 848 (84.3%) <0.001
  Asian or Asian British 348 (2.1%) 22 (2.2%)
  Black or Black British 271 (1.6%) 11 (1.1%)
  Mixed 32 (0.2%) *
  Any other ethnic group 184 (1.1%) 11 (1.1%)
  Unknown 2797 (16.6%) 111 (11.0%)
Comorbidities
  <5 9456 (56.2%) 660 (65.6%) <0.001
  5 to 10 1953 (11.6%) 104 (10.3%)
  10 to 15 3519 (20.9%) 153 (15.2%)
  15 to 20 1128 (6.7%) 54 (5.4%)
  >20 766 (4.6%) 35 (3.5%)
Type of cancer
  C17—malignant neoplasm of small intestine 526 (3.1%) 41 (4.1%) <0.001
  C22—malignant neoplasm of liver and Intrahepatic bile 
ducts
5069 (30.1%) 332 (33.0%)
  C23— malignant neoplasm of gallbladder 715 (4.3%) 45 (4.5%)
  C24—malignant neoplasm of other and unspecified 
parts of biliary tract
762 (4.5%) 74 (7.4%)
  C25—malignant neoplasm of pancreas 9750 (58%) 514 (51.1%)
  Pre- existing renal dysfunction 1747 (10.4%)   128 (12.7%)
  Previous ERCP 10 384 (61.8%)   631 (62.7%)
ERCP, endoscopic retrograde cholangiopancreatography.
lower 7- day (0.82 (95% CI 0.71 to 0.95), p=0.007) and 
30- day mortality (0.91 (95% CI 0.84 to 0.98), p=0.011).
30- day mortality was associated with deprivation (1.28 
(95% CI 1.13 to 1.44), p<0.001), increased comorbidity 
(Charlson index 20+, 3.10 (95% CI 2.64 to 3.65), p<0.001) 
and pre- existing renal dysfunction (2.37 (95% CI 2.12 to 
2.65), p<0.001), with 7- day mortality following a similar 
pattern.
Patients with unspecified bile duct cancer (1.28 (95% 
CI 1.08 to 1.52), p=0.004) or liver and intrahepatic bile 
duct cancer (1.04 (95% CI 1.14 to 1.24), p=0.004) had a 
higher 30- day mortality than those with pancreatic cancer. 
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Table 2 Rates of pre- and post- percutaneous transhepatic biliary drainage chemotherapy by age, cancer type and year of 
procedure
Type of cancer
Number of 
patients who had 
chemotherapy pre- 
PTBD
Number of 
patients who had 
chemotherapy post- 
PTBD Pvalue
C17—malignant neoplasm of small intestine 73 (13.9%) 100 (19%) <0.001
C22—malignant neoplasm of liver and intrahepatic bile ducts 251 (5%) 1011 (19.9%)
C23—malignant neoplasm of gallbladder 62 (8.7%) 122 (17.1%)
C24—malignant neoplasm of other and unspecified parts of 
biliary tract
24 (3.1%) 76 (10%)
C25—malignant neoplasm of pancreas 855 (8.8%) 2219 (22.8%)
  Age group
  <61 462 (14.1%) 1263 (38.7%) <0.001
  62–68 352 (11.4%) 937 (30.4%)
  69–74 279 (8.6%) 771 (23.7%)
  75–80 127 (3.7%) 461 (13.5%)
  ≥81 45 (1.2%) 96 (2.5%)
  Year of PTBD
  2001/2002 18 (2.0%) 115 (13.1%) <0.001
  2002/2003 48 (4.9%) 137 (13.9%)
  2003/2004 44 (4.8%) 142 (15.4%)
  2004/2005 68 (6.6%) 173 (16.8%)
  2005/2006 53 (4.7%) 206 (18.4%)
  2006/2007 73 (6.0%) 247 (20.5%)
  2007/2008 118 (8.9%) 286 (21.6%)
  2008/2009 98 (7.1%) 305 (22.0%)
  2009/2010 144 (9.2%) 345 (22.0%)
  2010/2011 152 (9.6%) 362 (22.8%)
  2011/2012 145 (8.9%) 384 (23.7%)
  2012/2013 149 (9.4%) 387 (24.5%)
  2013/2014 155 (9.6%) 439 (27.3%)
PTBD, percutaneous transhepatic biliary drainage.
Figure 1 Study flow chart. PTBD, percutaneous 
transhepatic biliary drainage.
Patients undergoing ERCP prior to PTBD also had lower 
30- day mortality (0.90 (95% CI 0.83 to 0.97), p=0.007).
Procedural factors and mortality
The results of the multivariate regression analysis of 
procedural factors associated with mortality are shown 
in table 4. There was a five- fold variation in 30- day 
mortality between providers, ranging from 9.1% to 50%. 
Compared with providers undertaking 1–15 PTBDs per 
year, there was a significantly decreased in- hospital and 
30- day mortality in providers performing 28–43 PTBDs 
per year (0.72 (95% CI 0.62 to 0.83), p<0.001 and 0.79 
(95% CI 0.69 to 0.89), p<0.001, respectively). In providers 
performing more than 44 PTBDs per year, there was an 
even larger decrease in in- hospital (0.68 (95% CI 0.57 
to 0.82), p<0.001), 7- day (0.54 (95% CI 0.40 to 0.74), 
p<0.001) and 30- day mortality (0.63 (95% CI 0.54 to 
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Figure 2 Kaplan Meier unadjusted analysis of 30- day 
mortality following percutaneous transhepatic biliary drainage 
for unresectable malignant disease by provider volume.
0.74), p<0.001). The effect of provider volume on 30- day 
mortality can be seen in figure 2.
The day of procedure had little influence on mortality 
with only Sunday having a higher in- hospital (2.54 (95% 
CI 1.66 to 3.91), p<0.001) and 30- day mortality (2.20 
(95% CI 1.47 to 3.28), p<0.001) compared with Monday 
to Thursday. However, the number of patients who had 
a PTBD on a Sunday was very small at 114 (0.7%) and 
therefore these results should be treated with caution. 
In- hospital mortality post- PTBD on multivariate analysis 
fell over the period studied, with persistently lower in- hos-
pital mortality between 2013 and 2014 (0.58 (95% CI 0.45 
to 0.74), p<0.001) compared with 2001/2002.
repeat Ptbd
The results of the multivariate analyses of factors associ-
ated with needing a further PTBD are shown in table 5. 
Patients undergoing an additional PTBD procedure within 
2 months of their initial PTBD were younger (81+years, 
0.21 (95% CI 0.16 to 0.27), p<0.001), less likely to have 
comorbidities (20+, 0.45 (95% CI 0.29 to 0.70), p<0.001) 
and were more likely to have cholangiocarcinoma (2.05 
(95% CI 1.77 to 2.37), p<0.001). Patients undergoing 
their procedure in a high- volume centre performing 
between 84 and 180 procedures per year were much less 
likely to require a second procedure within 2 months 
(0.47 (95% CI 0.36 to 0.62), p<0.001). The majority of 
patients underwent a repeat PTBD in the same centre, 
with only 222 patients (22.1%) being referred to another 
provider. Repeat PTBD procedures were usually under-
taken during emergency admissions (62.4%) rather than 
elective episodes (37.6%). 1923 patients (11.4%) under-
went an ERCP within 2 months of their initial PTBD.
dIsCussIon
This is the largest study to date examining the outcomes 
of patients undergoing PTBD for unresectable malig-
nant biliary tract obstruction. 7- day and 30- day mortality 
was 5.2% and 23.1%, respectively, with a median survival 
of 92 days. Reported 30- day mortality rates following 
PTBD vary considerably in the literature. In a 2008 
review examining PTBD case series, 30- day mortality for 
patients with distal biliary obstruction varied from 2% 
to 20% and for hilar lesions from 9% to 20%.2 However, 
30- day mortality has been reported to be as high as 39% 
in other case series.3 12–14 In 2012, the results of a large 
UK audit of biliary drainage and stenting procedures 
were published. This showed an in- hospital mortality 
of 19.8% in those with malignant biliary obstruction.15 
Finally, a 2018 randomised controlled trial examining 
outcomes in patients with perihilar cholangiocarcinoma 
was stopped prematurely because of a higher mortality in 
the PTBD group compared with the endoscopic group 
(41 vs 11%).16
Surgical or endoscopic drainage of the biliary system 
was not examined in this study. Surgical drainage is asso-
ciated with higher postoperative mortality and morbidity 
and an increased length of stay compared with non- 
surgical intervention.17–20 The choice between endo-
scopic or percutaneous biliary drainage is less clear, as few 
randomised trials exist.21 The decision often depends on 
the level of biliary obstruction. In England, PTBD is often 
the preferred technique for lesions above the common 
hepatic duct and when ERCP has failed.8 22 Endoscopic 
drainage, if technically possible, is probably perceived to 
be safer due to a small, very old, prospective randomised 
trial from 1987 in hilar and distal bile duct obstruction 
comparing the two techniques. The endoscopic approach 
had a higher success rate (81% vs 61%, p=0.017) and a 
lower 30- day mortality (15% vs 33%, p=0.016).23 However, 
only plastic stents were used in this study, which does not 
reflect current practice. There is only one randomised 
trial comparing PTBD with ERCP in hilar biliary obstruc-
tion due to gallbladder cancer.3 This demonstrated that 
PTBD had a higher success rate than ERCP (89% vs 41%, 
p<0.001) and a lower rate of early cholangitis (11% vs 
48%, p=0.02). In a recent meta- analysis comparing PTBD 
with ERCP for the relief of malignant jaundice, patients 
undergoing PTBD were less likely to develop cholan-
gitis compared with ERCP (0.55 (95% CI 0.36 to 0.84), 
p=0.006). However, there was no difference in success 
rate or 30- day mortality between the two approaches.24
The regression analysis in this study identified patients 
with an increased risk of death post PTBD. Older men, 
with increasing deprivation and comorbidity (especially 
pre- existing renal dysfunction), and those with a cancer 
type other than pancreatic had a worse prognosis. Over 
60% of patients in our cohort underwent a prior ERCP 
and this was expected, given that 62.5% of the patients 
had pancreatic or extra- hepatic cholangiocarcinoma. 
Undergoing an ERCP prior to PTBD was associated with 
lower mortality. This was likely to be due to a high propor-
tion of those patients undergoing ERCP having pancre-
atic cancer, which carried a better prognosis. Patient 
fitness to undergo a second biliary drainage procedure 
was also a likely contributing factor. A reduced mortality 
in providers performing a higher volume of PTBDs each 
year was identified. A number of factors may contribute 
to this difference including variability in peri- procedural 
 o
n
 January 31, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033576 on 23 January 2020. Downloaded from 
9Rees J, et al. BMJ Open 2020;10:e033576. doi:10.1136/bmjopen-2019-033576
Open access
Table 5 Multivariate regression analysis of factors associated with the need for a second percutaneous transhepatic biliary 
drainage for unresectable malignant disease
OR P value
Age group <61 1 (baseline group)
62–68 0.81 (0.68–0.97) 0.026
69–74 0.67 (0.56–0.81) <0.001
75–80 0.50 (0.41–0.61) <0.001
81+ 0.21 (0.16–0.27) <0.001
Sex Male 1 (baseline group)
Female 0.84 (0.74–0.96) 0.01
Comorbidity score <5 1 (baseline group)
5–10 0.86 (0.70–1.06) 0.161
10–15 0.70 (0.59–0.83) <0.001
15–20 0.30 (0.20–0.45) <0.001
20+ 0.45 (0.29–0.70) <0.001
Year of PTBD 2001/2002 1 (baseline group)
2002/2003 1.07 (0.69–1.67) 0.757
2003/2004 1.00 (0.63–1.57) 0.997
2004/2005 0.94 (0.60–1.48) 0.803
2005/2006 0.91 (0.58–1.42) 0.664
2006/2007 1.32 (0.88–1.99) 0.186
2007/2008 1.24 (0.82–1.86) 0.308
2008/2009 1.52 (1.03–2.26) 0.035
2009/2010 1.78 (1.22–2.60) 0.003
2010/2011 1.57 (1.07–2.31) 0.022
2011/2012 1.99 (1.37–2.90) <0.001
2012/2013 2.02 (1.39–2.94) <0.001
2013/2014 1.91 (1.31–2.79) 0.001
Deprivation score 1 (most deprived) 0.78 (0.63–0.97) 0.023
2 0.97 (0.79–1.19) 0.792
3 0.94 (0.77–1.15) 0.543
4 0.99 (0.81–1.21) 0.918
5 (least deprived) 1 (baseline group)
PTBD volume per 
year
<=15 1 (baseline group)
16–27 0.72 (0.60–0.87) 0.001
28–43 0.40 (0.32–0.50) <0.001
44–83 0.55 (0.42–0.72) <0.001
84–180 0.47 (0.36–0.62) <0.001
Type of cancer C17—malignant neoplasm of small intestine 1.47 (1.02–2.11) 0.038
C22—Malignant neoplasm of liver and intraheptic bile ducts 2.05 (1.77–2.37) <0.001
C23—Malignant neoplasm of gallbladder 1.68 (1.23–2.31) 0.001
C24—Malignant neoplasm of other and unspecified parts of 
biliary tract
1.12 (0.77–1.63) 0.55
C25—Malignant neoplasm of pancreas 1 (baseline group)
PTBD, percutaneous transhepatic biliary drainage.
care such as antibiotics and post- procedure management 
of complications such as sepsis and renal failure. Higher 
volume centres may also have a more rigorous approach 
to patient selection, with a greater emphasis on careful 
multi- disciplinary team discussion of management prior 
to PTBD. We recognise that it is not realistic to expect 
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all patients to be transferred to high volume centres for 
PTBD but the authors would recommend that PTBD 
outcomes are audited regularly and peri- procedural 
practices from high volume centres with good outcomes 
adopted in low volume centres.
Biliary obstruction in malignancy may result in pruritus, 
pain, cholangitis and liver failure.1 2 The goal of biliary 
drainage in inoperable patients is to improve quality of life 
and, in those with a good performance status, allow palli-
ative chemotherapy. Two studies have shown that biliary 
drainage can improve quality of life,3 4 and it has been 
shown that gemcitabine- based combinations improve 
progression free survival in pancreatic cancer (HR 0.78 
(95%CI 0.70-0.88)).5 A combination of gemcitabine and 
cisplatin can improve median survival in advanced biliary 
tract cancer from 8.1 to 11.7 months (HR 0.64 (95% 
CI 0.52 to 0.80), p<0.001).6 7 However, in our study, it 
is important to recognise that when considering PTBD, 
most patients did not receive chemotherapy after their 
procedure, with the rates decreasing significantly with 
age (aged <40 years 40.7% chemotherapy, aged 70 to 80 
17.4%, aged over 80 2.5%).
The rate of coded post- procedural complications in our 
study was high. 5.9% of patients were coded as experi-
encing a serious complication within 7 days, and 20.2% 
within 3 months. However, it was not possible to clarify 
the relationship between these later complications and 
the procedure or the underlying malignancy. Complica-
tion rates after PTBD vary between case series from 7% to 
30%,2 but cholangitis was common with rates of between 
9% and 11% reported.3 12–14 A UK audit reported a minor 
complication rate of 26% and a major complication rate 
of 7.9%, including a 3.5% rate of sepsis.16 It has therefore 
been recommended that all patients undergoing percu-
taneous drainage receive prophylactic antibiotics prior 
to their procedure.25–28 However, there are no national 
or international guidelines to date on this issue. Rates of 
cholangitis in these studies were higher in patients with 
a low serum albumin or raised C reactive protein, those 
with proximal or multiple points of intrahepatic biliary 
obstruction, neoplastic invasion or compression of the 
duodenum and if Staphylococcus aureus was present at the 
site of skin puncture. With these factors in mind, patients 
should be monitored closely post- PTBD for early signs of 
sepsis, and infection treated aggressively with intravenous 
antibiotics and fluids. Stent occlusion due to the deposi-
tion of a bacterial biofilm and biliary sludge or tumour 
overgrowth is an important late complication.29 In this 
study, stent blockage or displacement was coded in 6.2% 
of patients and rates in other series have been reported at 
between 5% and 27%.2 17 30 13.5% of patients in this study 
underwent more than one PTBD procedure. A 2008 
review of PTBD series reported recurrence of obstructive 
jaundice in between 5% and 25% of patients, with the 
majority undergoing a repeat PTBD.2
Every healthcare provider in England is required to 
submit diagnostic and procedural data to HES. However, 
the accuracy of the coding data submitted is a potential 
concern as it depends on the quality of the medical records 
and on the staff coding the records. HES produces a 
yearly report on the quality of the data received. In the 
2012/2013 report, 99.3% of primary diagnoses and 
99.9% of primary procedure codes were accurate.31 In 
order to validate the accuracy of diagnostic and proce-
dural coding relevant to this study, the number of PTBDs 
meeting the study criteria at UHB between 2009 and 2014 
was compared with the number submitted to HES. 321 
patients were recorded in HES as undergoing PTBD at 
UHB and 305 patients were identified from examining 
local radiology data, giving an accuracy of 95%. HES data 
are unfortunately not linked to cancer registry data, due 
to restrictions under which the data are held. Patients 
were therefore excluded who had very long periods 
following an apparent diagnosis of malignancy and PTBD 
and those with long delays in cancer diagnosis following 
PTBD. There are some important aspects of the patient’s 
care that are not recorded in HES. Information regarding 
the exact location of the lesion, the precise technique 
used (such as use of external drainage or type of stent 
placed) and whether the procedure was performed with 
ultrasound guidance, by a supervised trainee, or by an 
experienced interventional radiologist was not available. 
Important data such as whether any technical difficulties 
were encountered, performance status, bilirubin and 
albumin levels, clotting profile or inflammatory markers 
were also not available. In particular, prescription data 
regarding antibiotic use are not recorded, which limits 
our ability to investigate further the high frequency of 
septic complications. Recording of chemotherapy in HES 
may also not be entirely complete.31
In conclusion, 30- day mortality in patients under-
going PTBD for relief of unresectable malignant biliary 
obstruction was high at 23.1%. Older men and those 
with increasing comorbidity (especially pre- existing 
renal dysfunction) and deprivation have a poorer prog-
nosis. Patients undergoing a PTBD in a provider that 
performs more than 28 procedures per year have a 
significantly lower risk of death and there is a large varia-
tion in outcomes between providers. In light of the high 
mortality found in this study, the authors strongly recom-
mend that patients undergo careful multidisciplinary 
discussion prior to PTBD in order to identify risk factors 
for a poor outcome, to treat renal dysfunction and sepsis 
early, and to confirm that the patient is likely to benefit 
from PTBD, in terms of either symptom relief or as a 
bridge to chemotherapy.
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